Delivering mitochondrial health
This fall, Abliva's CEO, Ellen Donnelly will attend the two connected events LSX Inv€$tival Showcase and Jefferies London Healthcare Conference. On November 13 at 11:45 a.m., the Abliva's CEO, Ellen Donnelly, will present the company at LSX Inv€$tival Showcase. See the link below for more details.
In late November, Abliva will attend Nordic Life Science Days, at Bella Center in Copenhagen, Denmark. CEO Ellen Donnelly will be presenting the company during the session Biotechnology - Therapeutics & Diagnostics on November 29 at 2:12 p.m. CET in Auditorium 10. Follow the link below for more details.
In early January 2024, Abliva's CEO, Ellen Donnelly, will attend the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, USA. The conference is a healthcare investment symposium that connects global industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. Follow the link below to learn more.
In mid-March, Abliva will attend the 8th edition of Mitochondrial Medicine - Therapeutic Development in Hinxton, UK. This annual scientific meeting is focused on mitochondrial disorders and the search for novel effective therapies. Abliva's CMO, Maguns Hansson, will join the panel discussion Challenges and opportunities in clinical trials: perspectives from pharma and funders, where representatives from […]
In mid-April, Abliva will participate at Kempen Life Sciences Conference in Amsterdam, The Netherlands. For more information, please click the link below.
In mid-May, Abliva will travel to the Bio€quity Europe meeting in San Sebastán, Spain. "For more than 20 years, Bio€quity Europe has been where CEOs and investors gather to network, partner, and debate critical issues facing the biotech industry." Abliva's CEO, Ellen Donnelly, will, together with the company's CMO, Magnus Hansson, be networking and presenting […]
Join Abliva for a virtual KOL event featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently no approved medicines for the systemic disease. The event will focus on Abliva's lead program, KL1333, which has shown clinically meaningful, […]
In early June, Abliva's CEO, Ellen Donnelly, travels to San Diego to attend BIO International 2024. Follow the link below for more information.
In late June, Abliva will attend the US patient organization UMDF’s Mitochondrial Medicine Conference in Cleveland, Ohio. "Each year, UMDF’s Mitochondrial Medicine Conference brings together the best minds in mitochondrial medicine and the patients we serve. With over 700 attendees representing almost every state in the U.S. and more than 15 different countries, the Conference […]
In September, Abliva will attend the Nordic Life Science Days (NLS days) in Malmö, Sweden. Ablia's CEO, Ellen Donnelly, will be presenting the company at 11:00 a.m. CET on September 18, in the session Biotechnology. Follow the link below for more information.
In late October, Abliva will attend the 14th Mitochondrial Disease Conference, this year in Padua (IT), organized by the Italian patient organization Mitocon. Abliva's CMO, Magnus Hansson will attend the session: Roundtable with Pharmaceutical Industries and Regulatory Authorities. Read more by following the link below.
In early November, Abliva's CEO, Ellen Donnelly, will attend the BIO-Europe meeting in Stockholm, Sweden. On Monday, November 4, Ellen will be presenting the company at 4:30 p.m. CET. Follow the link below for further details.
